DE69527966T2 - Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viii - Google Patents
Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viiiInfo
- Publication number
- DE69527966T2 DE69527966T2 DE69527966T DE69527966T DE69527966T2 DE 69527966 T2 DE69527966 T2 DE 69527966T2 DE 69527966 T DE69527966 T DE 69527966T DE 69527966 T DE69527966 T DE 69527966T DE 69527966 T2 DE69527966 T2 DE 69527966T2
- Authority
- DE
- Germany
- Prior art keywords
- factor viii
- factor
- subcutaneous
- pct
- intradermal administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9401105A SE9401105D0 (sv) | 1993-07-05 | 1994-03-31 | Formulation |
SE9500036A SE9500036D0 (sv) | 1995-01-05 | 1995-01-05 | Formulation |
PCT/SE1995/000348 WO1995026750A1 (en) | 1994-03-31 | 1995-03-31 | Pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration of factor viii or factor ix |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69527966D1 DE69527966D1 (de) | 2002-10-02 |
DE69527966T2 true DE69527966T2 (de) | 2003-05-28 |
Family
ID=26662019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69527966T Expired - Lifetime DE69527966T2 (de) | 1994-03-31 | 1995-03-31 | Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viii |
Country Status (19)
Country | Link |
---|---|
US (1) | US5925739A (de) |
EP (1) | EP0772452B1 (de) |
JP (1) | JP3939750B2 (de) |
AT (1) | ATE222770T1 (de) |
AU (1) | AU690666B2 (de) |
BR (1) | BRPI9507227B8 (de) |
CA (1) | CA2186126C (de) |
DE (1) | DE69527966T2 (de) |
DK (1) | DK0772452T3 (de) |
ES (1) | ES2182899T3 (de) |
FI (1) | FI118171B (de) |
HU (1) | HU223314B1 (de) |
IL (2) | IL113010A (de) |
NO (1) | NO321139B1 (de) |
NZ (1) | NZ283499A (de) |
PL (1) | PL180282B1 (de) |
PT (1) | PT772452E (de) |
TW (1) | TW400234B (de) |
WO (1) | WO1995026750A1 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4430205A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung |
SE9403915D0 (sv) * | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
SE9502285D0 (sv) | 1995-06-22 | 1995-06-22 | Pharmacia Ab | Improvements related to injections |
US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
WO1997039761A1 (en) * | 1996-04-19 | 1997-10-30 | Alpha Therapeutic Corporation | A process for viral inactivation of lyophilized blood proteins |
US7560107B2 (en) * | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
US7786070B2 (en) | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
US20050032690A1 (en) * | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
PT2130554E (pt) | 1999-02-22 | 2012-11-19 | Univ Connecticut | Formulações de factor viii isentas de albumina |
US8465468B1 (en) * | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
US20020156453A1 (en) * | 1999-10-14 | 2002-10-24 | Pettis Ronald J. | Method and device for reducing therapeutic dosage |
JP4663837B2 (ja) * | 1999-12-24 | 2011-04-06 | 一般財団法人化学及血清療法研究所 | 第▲viii▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物 |
US20020123093A1 (en) | 2000-04-06 | 2002-09-05 | Zannis Vassilis I. | Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia |
EP1280548B1 (de) | 2000-05-03 | 2013-12-11 | Novo Nordisk Health Care AG | Subkutane Verabreichung des Koagulationsfaktor VII |
RU2357751C2 (ru) | 2001-12-21 | 2009-06-10 | Ново Нордиск Хелт Кэр Аг | Жидкая композиция полипептидов фактора vii |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
EP2283856B1 (de) | 2002-06-21 | 2017-09-20 | Novo Nordisk Health Care AG | Stabiliserte feste Zusammensetzungen von Faktor VIIa Polypeptiden |
WO2004082708A2 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
US7977460B2 (en) * | 2003-05-19 | 2011-07-12 | National Institute For Biological Standards And Control | Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B |
DE602004025100D1 (de) * | 2003-05-23 | 2010-03-04 | Novo Nordisk Healthcare Ag | Stabilisierung von proteinen in lösung |
ES2382157T3 (es) * | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
JP5306597B2 (ja) * | 2003-07-01 | 2013-10-02 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii因子ポリペプチドの液体水性薬学的組成物 |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
ES2574581T3 (es) | 2003-08-14 | 2016-06-20 | Novo Nordisk Health Care Ag | Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII |
ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
AU2004298789A1 (en) * | 2003-12-19 | 2005-06-30 | Novo Nordisk Health Care Ag | Stabilised compositions of factor VII polypeptides |
FR2868704B1 (fr) * | 2004-04-07 | 2007-09-14 | Ethypharm Sa | Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires |
ES2449044T3 (es) * | 2004-05-03 | 2014-03-18 | Emory University | Procedimiento de administración de fVIII sin dominio B porcino |
EP1771066A2 (de) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1 |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
EP1824988B1 (de) * | 2004-11-12 | 2017-04-19 | Bayer HealthCare LLC | Ortsgerichtete modifizierung von fviii |
NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
US20080227691A1 (en) * | 2005-04-01 | 2008-09-18 | Novo Nordisk Health Care Ag | Blood Coagulation FVIII Analogues |
EP2386571B1 (de) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
ES2516694T3 (es) | 2006-07-21 | 2014-10-31 | Ratiopharm Gmbh | Glicosilación de péptidos a través de secuencias de glicosilación con unión en O |
WO2008057683A2 (en) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
US20100143326A1 (en) * | 2007-01-03 | 2010-06-10 | Novo Nordisk Healthcare A/G | SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES |
BRPI0809670A8 (pt) | 2007-04-03 | 2018-12-18 | Biogenerix Ag | métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral. |
KR101578561B1 (ko) * | 2007-04-26 | 2015-12-17 | 바이엘 헬스케어 엘엘씨 | 냉동 저장을 위한, 재조합 단백질의 액상 용액의 안정화 |
CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
PL2167117T3 (pl) * | 2007-06-13 | 2013-01-31 | Csl Behring Gmbh | Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi |
CN103497246B (zh) * | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
EP2352515A4 (de) * | 2008-11-03 | 2012-04-25 | Bayer Healthcare Llc | Verfahren zur behandlung von hämophilie |
US20100168018A1 (en) | 2008-11-07 | 2010-07-01 | Baxter International Inc. | Factor viii formulations |
CA2770609A1 (en) * | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
SG190136A1 (en) | 2010-11-05 | 2013-07-31 | Baxter Int | A new variant of antihemophilic factor viii having increased specific activity |
EP2768522B1 (de) | 2011-10-18 | 2016-07-27 | CSL Behring GmbH | Verwendung sulfatierter glycosaminglycane zur verbesserung der bioverfügbarkeit von blutgerinnungsfaktoren |
AU2012318303B2 (en) | 2011-10-18 | 2015-09-03 | Csl Behring Gmbh | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII |
US20150086524A1 (en) * | 2012-04-16 | 2015-03-26 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
HUE047933T2 (hu) | 2013-03-15 | 2020-05-28 | Bioverativ Therapeutics Inc | Faktor VIII polipeptid készítmények |
AU2013203062C1 (en) | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
EP2796145B1 (de) | 2013-04-22 | 2017-11-01 | CSL Ltd. | Ein kovalenter komplex bestehend aus von willebrand und faktor viii verbunden mit einer disulfidbrücke |
KR20170010895A (ko) | 2014-06-06 | 2017-02-01 | 옥타파마 아게 | 인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제 |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
CA3029887A1 (en) | 2016-07-08 | 2018-01-11 | CSL Behring Lengnau AG | Subcutaneous administration of long-acting factor ix in humans |
TW201828974A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Csl貝林重組技能公司 | 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類 |
US20230190881A1 (en) | 2020-02-17 | 2023-06-22 | Biotest Ag | Subcutaneous administration of factor viii |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56127308A (en) * | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical |
US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
FI86885C (fi) * | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
SE8501050D0 (sv) * | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
US5576194A (en) * | 1986-07-11 | 1996-11-19 | Bayer Corporation | Recombinant protein production |
SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
NL9001681A (nl) * | 1990-07-24 | 1992-02-17 | Rijksuniversiteit | Transmucosale geneesmiddelpreparaten en transmucosale toediening. |
ATE173405T1 (de) * | 1991-07-10 | 1998-12-15 | Takeda Chemical Industries Ltd | Arzneimittel auf basis von hyaluronsäure |
GB9122609D0 (en) * | 1991-10-24 | 1991-12-04 | Brownlee George G | Improvements relating to the treatment of haemophilia |
DE69333928T2 (de) * | 1992-04-30 | 2006-08-17 | Probitas Pharma Inc., Los Angeles | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes |
GB9211538D0 (en) * | 1992-06-01 | 1992-07-15 | Blake David R | Antiinflammatory agent |
JP3905921B2 (ja) * | 1992-10-02 | 2007-04-18 | ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー | 凝固第▲viii▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法 |
SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
-
1995
- 1995-03-16 IL IL11301099A patent/IL113010A/xx not_active IP Right Cessation
- 1995-03-16 IL IL11301095A patent/IL113010A0/xx unknown
- 1995-03-17 TW TW084102570A patent/TW400234B/zh not_active IP Right Cessation
- 1995-03-31 WO PCT/SE1995/000348 patent/WO1995026750A1/en active IP Right Grant
- 1995-03-31 NZ NZ283499A patent/NZ283499A/xx not_active IP Right Cessation
- 1995-03-31 HU HU9602693A patent/HU223314B1/hu not_active IP Right Cessation
- 1995-03-31 ES ES95914669T patent/ES2182899T3/es not_active Expired - Lifetime
- 1995-03-31 AT AT95914669T patent/ATE222770T1/de active
- 1995-03-31 DK DK95914669T patent/DK0772452T3/da active
- 1995-03-31 EP EP95914669A patent/EP0772452B1/de not_active Expired - Lifetime
- 1995-03-31 BR BRPI9507227A patent/BRPI9507227B8/pt not_active IP Right Cessation
- 1995-03-31 CA CA002186126A patent/CA2186126C/en not_active Expired - Fee Related
- 1995-03-31 AU AU21560/95A patent/AU690666B2/en not_active Ceased
- 1995-03-31 DE DE69527966T patent/DE69527966T2/de not_active Expired - Lifetime
- 1995-03-31 US US08/716,140 patent/US5925739A/en not_active Expired - Lifetime
- 1995-03-31 PT PT95914669T patent/PT772452E/pt unknown
- 1995-03-31 PL PL95316618A patent/PL180282B1/pl not_active IP Right Cessation
- 1995-03-31 JP JP52561695A patent/JP3939750B2/ja not_active Expired - Fee Related
-
1996
- 1996-09-27 NO NO19964081A patent/NO321139B1/no not_active IP Right Cessation
- 1996-09-27 FI FI963871A patent/FI118171B/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL316618A1 (en) | 1997-01-20 |
JP3939750B2 (ja) | 2007-07-04 |
HU223314B1 (hu) | 2004-05-28 |
CA2186126A1 (en) | 1995-10-12 |
FI963871A (fi) | 1996-09-27 |
ATE222770T1 (de) | 2002-09-15 |
EP0772452A1 (de) | 1997-05-14 |
TW400234B (en) | 2000-08-01 |
DE69527966D1 (de) | 2002-10-02 |
HU9602693D0 (en) | 1996-11-28 |
PT772452E (pt) | 2003-01-31 |
WO1995026750A1 (en) | 1995-10-12 |
EP0772452B1 (de) | 2002-08-28 |
HUT74918A (en) | 1997-03-28 |
NO321139B1 (no) | 2006-03-27 |
FI963871A0 (fi) | 1996-09-27 |
MX9604455A (es) | 1997-07-31 |
IL113010A (en) | 1999-10-28 |
BRPI9507227B8 (pt) | 2015-12-08 |
US5925739A (en) | 1999-07-20 |
NO964081L (no) | 1996-11-29 |
CA2186126C (en) | 2007-11-20 |
JPH10501522A (ja) | 1998-02-10 |
IL113010A0 (en) | 1995-10-31 |
DK0772452T3 (da) | 2003-01-06 |
ES2182899T3 (es) | 2003-03-16 |
NO964081D0 (no) | 1996-09-27 |
AU2156095A (en) | 1995-10-23 |
BR9507227A (pt) | 1997-09-09 |
PL180282B1 (pl) | 2001-01-31 |
NZ283499A (en) | 1997-08-22 |
FI118171B (fi) | 2007-08-15 |
AU690666B2 (en) | 1998-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69527966D1 (de) | Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viii | |
SE9302308L (sv) | Proteinberedning | |
IL135712A (en) | Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis | |
DE69132688D1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
MY105798A (en) | Treatment of leukocyte dysfunction with gm-csf. | |
DE69921348D1 (de) | Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |